GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 04:48:26 2024-12-04 am EST			5-day change	1st Jan Change
1,353.75 ^GBX	-1.04%		+0.78%	-6.60%

10:28am	Vodafone taps former GSK CFO Simon Dingemans as non-executive director	AN
Dec. 03	Hansoh Pharmaceutical Group Company Limited : Regulator grants breakthrough-therapy status to lung cancer drug

GSK: EU approves single-dose presentation of Menveo vaccine

November 27, 2024 at 04:16 am EST

GSK announces that the European Commission has approved a new single-dose, ready-to-use presentation of Menveo, a meningococcal group A, C, W-135 and Y conjugate vaccine.

This version is approved for the active immunization of children from the age of 2, adolescents and adults, simplifying administration for healthcare professionals.

GSK's submission is based on two Phase IIb trials demonstrating comparable immunogenicity, tolerability and safety profile to the existing version.

Philip Dormitzer, Head of Vaccines R&D at GSK, underlines the company's commitment to innovation to increase access to vaccination against bacterial meningitis in the European Union.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Latest news about GSK plc

Vodafone taps former GSK CFO Simon Dingemans as non-executive director	04:28am	AN
Hansoh Pharmaceutical Group Company Limited : Regulator grants breakthrough-therapy status to lung cancer drug	Dec. 03
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	Dec. 03	MT
GSK : JP Morgan reiterates its Sell rating	Dec. 03	ZD
Berenberg Lowers Price Target on GSK to GBP16 From GBP18.20, Maintains Buy Rating	Dec. 02	MT
GSK : Berenberg reiterates its Buy rating	Dec. 02	ZD
Deutsche Bank raises AB Foods and Burberry	Dec. 02	AN
Wall Street hit by turkey coma	Nov. 29
Intron Health Downgrades GSK to Sell, Cuts PT	Nov. 29	MT
Analyst recommendations: Apple, Dell, Pfizer, Wall Disney, GSK...	Nov. 29
UK Shares Tick Up as Market Watchers Await Key US Inflation Data	Nov. 27	MT
GSK Says EC Approved Fully Liquid Menveo as Meningococcal Vaccine	Nov. 27	MT
GSK hails EU Approval of Menveo vaccine in new format	Nov. 27	AN
GSK: EU approves single-dose presentation of Menveo vaccine	Nov. 27	CF
GSK's Liquid Meningitis Vaccine Gets EU Authorization	Nov. 27	DJ
GSK Obtains EU Nod for Liquid Form of Meningococcal Vaccine	Nov. 27	MT
Gsk Plc's Fully Liquid Menveo Meningococcal Vaccine Approves by European Commission	Nov. 27	CI
Global markets live: Palantir, Apple, Tesla, Boeing, Nvidia...	Nov. 25
GSK : Goldman Sachs reaffirms its Neutral rating	Nov. 25	ZD
GSK Cancer Therapy Candidate Accepted for FDA Review	Nov. 25	MT
GSK: applies to the FDA for multiple myeloma treatment	Nov. 25	CF
GSK's Blenrep combinations accepted for review by US FDA	Nov. 25	AN
US FDA Accepts GSK's License Application for Myeloma Combination Treatments for Review	Nov. 25	MT
GSK plc Announces Us Food and Drug Administration Accepted for Review Biologics License Application for Blenrep (Belantamab Mafodotin)	Nov. 25	CI
FTSE 100 Closes Week in Green; UK Retail Sales, Business Activity Contract	Nov. 22	MT

Chart GSK plc

Duration

Period

GSK: Dynamic Chart

Company Profile

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

70,212

Sector

Pharmaceuticals

Calendar

2024-12-03 - Evercore ISI HealthCONx Conference

More about the company